212 related articles for article (PubMed ID: 16317736)
1. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
3. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
4. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
[TBL] [Abstract][Full Text] [Related]
7. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA
Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104
[TBL] [Abstract][Full Text] [Related]
9. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.
Navari RM; Koeller JM
Ann Pharmacother; 2003 Sep; 37(9):1276-86. PubMed ID: 12921512
[TBL] [Abstract][Full Text] [Related]
10. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
[TBL] [Abstract][Full Text] [Related]
12. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
[TBL] [Abstract][Full Text] [Related]
13. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
Anastasia PJ
Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists].
Abenhardt W; Bosse D; Böning L; Bojko P; Hitz H; Völkl S; Fromm M; Mittermüller J; Göldel N; Schick HD; Dietzfelbinger H; Hinke A
Dtsch Med Wochenschr; 2006 Dec; 131(48):2707-12. PubMed ID: 17123235
[TBL] [Abstract][Full Text] [Related]
16. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
Constenla M
Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
Haus U; Späth M; Färber L
Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
[TBL] [Abstract][Full Text] [Related]
19. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
[TBL] [Abstract][Full Text] [Related]
20. The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers.
Youlten L
J Pharm Pharmacol; 2004 Feb; 56(2):169-75. PubMed ID: 15005875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]